RTx-161
Based on 1 Customer Validation
RTx-161 is a DNA polymerase θ inhibitor with an IC50 of 4.1 nM. RTx-161 induces DNA damage, PARP cleavage, apoptosis, and selectively kills homologous recombination-deficient (HRD) cells. RTx-161 acts synergistically with PARP inhibitors to suppress PARP inhibitor resistance in cancer cells. RTx-161 can be used for the research of BRCAG12C mutant cancer and HR-deficient cancers.
For research use only. We do not sell to patients.
- Purity : 98.0%
- CAS No.: 3035072-49-9
- Formula: C21H18F7N3O4
- Molecular Weight:509.37
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
All DNA/RNA Synthesis Isoforms
More
Biological Activity
Description
In Vitro
RTx-161 (1 μM; 60 min) has poor metabolic stability in mouse CD1 male liver microsomes, with a half-life of <2 min[1].
RTx-161 (10-12 day) selectively inhibits colony formation in BRCA2-/- HCT116 cells with an IC50 of 1.4 μM, while having minimal effect on BRCA2+/+ HCT116 cells (IC50 >8 μM)[1].
RTx-161 binds to an allosteric pocket of PolθΔL in complex with DNA and ddGTP, forming specific hydrophobic and hydrogen bond interactions, with a structure resolved to 3.31 Å resolution[1].
RTx-161 (4-500 nM; 15 min) concentration-dependently inhibits recombinant human Polθ-pol MMEJ activity in a cell-free in vitro assay, with maximal inhibition at 500 nM[2].
RTx-161 (2 μM; 0-40 min) does not significantly inhibit recombinant human Polθ-pol ddCMP incorporation on open-conformation DNA/RNA primer-templates in a cell-free assay[2].
RTx-161 (Varying concentrations up to 16 μM; 10-12 days) selectively reduces the survival of HR-deficient cell lines (BRCA2-null DLD1, BRCA2-null HCT116, PALB2-mutant EUFA1341, Brca1cc/cc MEFs) in clonogenic assays, with minimal effect on HR-proficient controls[2].
RTx-161 (20 μM; 16 h) suppresses MMEJ repair of site-specific DSBs in U2OS cells expressing a chromosomal GFP reporter cassette[2].
RTx-161 selectively induces DNA damage (measured by γ-H2AX foci and protein levels) in BRCA2-null DLD1 cells, with minimal effect on BRCA2-WT DLD1 cells[2].
RTx-161 selectively induces apoptosis (measured by PARP cleavage) in BRCA2-null DLD1 cells, with no significant effect on BRCA2-WT DLD1 cells[2].
RTx-161 (0.5-10 μM; 10-12 days) acts synergistically with PARP inhibitors (Olaparib (HY-10162), Rucaparib (HY-10617A), Talazoparib (HY-16106)) to reduce survival of HR-deficient cell lines (BRCA2-null HCT116, BRCA2-null DLD1, PE01, VC8, CAPAN-1) and modestly potentiates Talazoparib activity in HR-proficient MDA-MB-231 cells in clonogenic assays[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:BRCA2-null HCT116, BRCA2-null DLD1, PE01 (BRCA2-mutant ovarian), VC8 (BRCA2-truncating mutant hamster), CAPAN-1 (BRCA2-pathogenic mutant pancreatic), MDA-MB-231 (HR-proficient triple-negative breast)
-
Concentration:0.5; 5; 10 μM
-
Incubation Time:10-12 days
-
Result:Exhibited strong synergistic activity with Olaparib in BRCA2-null HCT116, BRCA2-null DLD1, PE01, VC8, and CAPAN-1 cells.
Modestly potentiated Talazoparib activity in HR-proficient MDA-MB-231 cells.
Chemical Information
-
CAS No. 3035072-49-9
-
Appearance Solid
-
Molecular Weight 509.37
-
Formula C21H18F7N3O4
-
Color Colorless to off-white
-
SMILES
FC(F)(F)C1=CC(N2CCN(CCO)C2=O)=C(OC(N(C3=CC=C(F)C=C3)C)=O)C(C(F)(F)F)=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
CRISPR-Cas9 HDR knock-in/precise editing
CRISPR-Cas9 HDR knock-in uses a guide RNA to direct Cas9 to a genomic target adjacent to a PAM, where Cas9 creates a double-strand break; if a donor DNA template with homology to the cut region is present, cellular HDR can copy the donor sequence into the genome, producing a precise substitution, tag, reporter, or insertion rather than an indel. The readout is the fraction of alleles or cells carrying the intended donor-derived edit, measured by junction PCR, restriction-fragment analysis, Sanger sequencing, amplicon deep sequencing, flow cytometry for reporter knock-in, or clone genotyping; NHEJ indels and partial or non-HDR insertions are measured in parallel because they compete with or confound precise HDR outcomes.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Genotoxicity/Mutagenicity Study
The bacterial reverse mutation assay detects point mutations that restore amino-acid prototrophy in auxotrophic Salmonella typhimurium or Escherichia coli tester strains; after exposure to a test article, mutagenic activity is read out as an increased number of revertant colonies on minimal agar compared with the vehicle control. The assay uses tester strains with different mutation targets so that base-substitution and frameshift mutagens can be detected, and testing is performed with and without exogenous mammalian metabolic activation because some chemicals require biotransformation to become mutagenic.
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Chandramouly G, et al. RTx-303, an Orally Bioavailable Polθ Polymerase Inhibitor That Potentiates PARP Inhibitors in BRCA Mutant Tumors. J Med Chem. 2025;68(21):22196-22215. [Content Brief]
[2]. Fried W, et al. Discovery of a small-molecule inhibitor that traps Polθ on DNA and synergizes with PARP inhibitors. Nat Commun. 2024;15(1):2862. Published 2024 Apr 5. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)